8-K: Zynex Reports Steep Q2 Loss Amid Revenue Decline and Leadership Transition

Zynex, Inc. announced a significant net loss of $20.0 million in Q2 2025, down from a $1.2 million profit in the prior year, driven by a sharp revenue decline and operational restructuring, while also appointing a new CEO and submitting a new product to the FDA.

Summary

• Net revenue for the second quarter ended June 30, 2025, was $22.3 million, a substantial decrease compared to $49.9 million in the prior year quarter.
• The company reported a net loss of $20.0 million, or $0.66 per basic and diluted share, for Q2 2025, which includes a non-cash adjustment of $10.3 million ($0.34 per share) related to an allowance on deferred tax assets.
• Gross profit for Q2 2025 was $15.2 million, representing 68% of revenue, down from $39.9 million, or 80% of revenue, in Q2 2024.
• Sales and marketing expenses decreased by 45% to $12.8 million in Q2 2025 from $23.2 million in Q2 2024, primarily due to reduced sales force headcount.
• Adjusted EBITDA loss for Q2 2025 was $8.9 million, compared to Adjusted EBITDA of $3.5 million in Q2 2024.
• Cash flow from operations was a deficit of $6.2 million for Q2 2025 and $16.7 million year-to-date.
• Cash and cash equivalents stood at $17.5 million as of June 30, 2025, a decrease from $39.6 million at December 31, 2024.
• The company expects annualized savings of approximately $40 million from efficiency improvements, with most taking full effect in the third and fourth quarters of 2025.
• Zynex has temporarily suspended revenue and profitability guidance due to the retirement of the current CEO and the announced departure of the CFO.

Sentiment

Score: 3

Explanation: The financial results are significantly negative across key metrics (revenue, net income, EBITDA, cash flow, cash balance). While there are positive strategic moves (new CEO, FDA submission, cost savings plan), the immediate financial performance is very poor, and the suspension of guidance adds uncertainty. The large convertible note coming due is also a concern.

Positives

• Steven Dyson was appointed as the new CEO, bringing over 25 years of experience in the medical technology sector.
• The NiCO laser pulse oximeter was submitted to the FDA, marking a significant product development milestone in patient monitoring.
• Efficiency improvements and restructuring efforts are expected to result in annualized savings of approximately $40 million, primarily impacting Q3 and Q4 2025.
• Sales and marketing expenses decreased by 45% due to reduced headcount, indicating successful cost control measures.
• The sequential quarterly reduction in the deficit of cash from operations suggests initial positive impact from expense reductions.

Negatives

• Net revenue significantly declined to $22.3 million in Q2 2025 from $49.9 million in Q2 2024, negatively affected by Tricare payment suspension and operational changes.
• The company swung from a net income of $1.2 million in Q2 2024 to a net loss of $20.0 million in Q2 2025.
• Gross profit margin decreased to 68% in Q2 2025 from 80% in Q2 2024.
• Adjusted EBITDA shifted from a positive $3.5 million in Q2 2024 to a loss of $8.9 million in Q2 2025.
• Cash flow from operations was negative $6.2 million for Q2 2025 and negative $16.7 million year-to-date.
• Cash and cash equivalents significantly decreased to $17.5 million as of June 30, 2025, from $39.6 million at December 31, 2024.
• The company temporarily suspended revenue and profitability guidance due to leadership changes, adding uncertainty.
• Retained earnings moved into a deficit of ($655k) from a positive $29.774 million.
• Total stockholders' equity significantly decreased to $1.261 million from $35.708 million.

Risks

• The need to obtain CE marking for new products.
• The acceptance of new and existing products by doctors and hospitals.
• Competition from larger competitors with greater financial resources.
• The need to keep pace with technological changes.
• Dependence on reimbursement for products from health insurance companies.
• The uncertain outcome of the Tricare payment suspension.
• Dependence on third-party manufacturers to produce products on time and to specifications.
• Challenges in implementing the sales strategy, including maintaining a strong direct sales force.
• Adverse market conditions.
• Economic factors, such as interest rate fluctuations.

Future Outlook

The company has temporarily suspended revenue and profitability guidance due to the retirement of the current Chief Executive Officer and the announced departure of the Chief Financial Officer. The incoming Chief Executive Officer, Steven Dyson, will lead a review of the company's forecasting procedures and plans to provide an update on the potential resumption of guidance in the coming quarters. Management expresses confidence that cost reduction efforts and sales force redirection will be pivotal to improved cash flow and create a foundation for continuing to grow into the huge demand for their products.

Management Comments

• "In the second quarter of 2025, we completed two transformational events. First, we appointed Steven Dyson as our new CEO. Steven brings over 25 years of experience in the medical technology sector, primarily through his leadership at Apax, a global private equity firm. Steven brings deep expertise and a proven track record in the medical sector. His leadership will be instrumental as we refocus our business strategy toward a more optimized payer mix and work to return Zynex to a strong growth trajectory." Thomas Sandgaard, Founder and CEO of Zynex.
• "Second, we submitted our NiCO laser pulse oximeter to the FDA. This submission marks a historic milestone in the evolution of pulse oximetry and a major breakthrough in our mission to improve the quality of care and patient outcomes through our patient monitoring products." Thomas Sandgaard, Founder and CEO of Zynex.
• "During the quarter we continued our efforts to refocus our sales force and operations to reflect the current landscape of insurance coverage and have made significant strides towards our goal of returning to positive cash-flow."
• "We have implemented several efficiency improvements to internal operations, reallocating staff to more profitable business lines, reducing our cost of goods sold, and updating our organizational structure while driving the sales force to become more efficient and productive. These improvements will result in annualized savings of approximately $40 million, most of which will take full effect in the third and fourth quarters of this year."
• "We strongly believe in our commitment to help patients with the best products for pain relief without the side effects that are associated with opioids. We are confident that our efforts to reduce costs and redirecting our sales force will be pivotal to improved cash flow and create a foundation for continuing to grow into the huge demand for our products."

Industry Context

Zynex operates in the medical technology sector, specializing in pain management, rehabilitation, and patient monitoring. The submission of the NiCO laser pulse oximeter to the FDA indicates a focus on innovation within patient monitoring, a growing area. The challenges with Tricare payment suspension and the need to optimize payer mix highlight the significant impact of healthcare reimbursement policies on medical device companies. The company's strategic shift towards cost efficiency and a more profitable business model reflects broader industry pressures to adapt to changing insurance landscapes and control operational costs. The emphasis on non-opioid pain relief aligns with current healthcare trends addressing the opioid crisis.

Management Changes

Stakeholder Impact

• Shareholders: Significant net loss, revenue decline, and negative cash flow could lead to decreased share value. The suspension of guidance adds uncertainty. The appointment of a new CEO and planned cost-saving initiatives offer potential for future recovery.
• Employees: Sales force headcount decreased, indicating job reductions as part of restructuring. Staff reallocated to more profitable business lines.
• Customers: Changes to shipment and billing procedures aim to improve patient experience. The company continues to support new and existing Tricare patients despite no related revenue.
• Creditors: The reclassification of $59.1 million in convertible senior notes to current liabilities indicates a significant short-term financial obligation, potentially impacting the company's credit profile.

Next Steps

• Incoming CEO Steven Dyson will lead a review of the company's forecasting procedures.
• Steven Dyson will provide an update to investors on the potential resumption of guidance in the coming quarters.
• Most of the $40 million annualized savings from efficiency improvements are expected to take full effect in the third and fourth quarters of 2025.
• A conference call and webcast are scheduled for July 31, 2025, to discuss the Q2 2025 results.

Key Dates

Recommendation

The company reported a substantial decline in revenue, a significant net loss, and negative cash flow from operations, indicating severe financial deterioration. The gross profit margin also decreased. While the appointment of a new CEO and planned cost savings are positive strategic moves, the immediate financial performance is alarming. The temporary suspension of guidance adds to the uncertainty, and the reclassification of a large convertible senior note to current liabilities highlights a significant near-term financial obligation. These factors suggest a high degree of risk and a negative outlook for the stock in the short to medium term.

Keywords

Medical Devices, Pain Management, Patient Monitoring, Rehabilitation, SEC Filing, Financial Results, Q2 2025, Zynex, ZYXI, FDA Submission, CEO Change, Cost Savings, Tricare, Pulse Oximeter, Earnings